AZD8055

ArtNr	S1555-10
Hersteller	Selleckchem
CAS-Nr.	1009298-09-2
Menge	10 mg
Quantity options	10 mg 1 g 10 g 10 mM/1 mL 5 mg 50 mg 5 g
Kategorie	Oncology Neuroscience Neural Lineage Markers Neuroinflammation Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Heart & Blood Cancer
Typ	Inhibitors
Specific against	other
Smiles	CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOCC5C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1009298-09-2'
Similar products	AZD8055
Lieferbar
Manufacturer - Targets	MTOR
Storage Conditions	2 years -80 in solvent
Molecular Weight	465, 54
Administration	Oral gavage once or twice daily
Animal Models	U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG and A549 are established in pathogen-free, female nude mice (nu/nu:Alpk).
Cell lines	U87MG, A549 and H838 cells
Clinical Trials	Currently under Phase I clinical trial in adults with recurrent gliomas.
Concentrations	1 nM - 1 uM
Dosages	2.5-20 mg/kg
Formulation	Dissolved in captisol (CyDex, pH 3.0) and diluted to a final captisol concentration of 30% (w/v)
IC50	0.8 nM, 0.8 nM, 0.8 nM, 0.8 nM, 0.8 nM, 0.8 nM
In vitro	AZD8055 shows low activity ( 1, 000-fold) against all PI3K isoforms (alpha, beta, gamma, delta) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. [1] AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. [2] AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7 nM and induces significant differences in EFS distribution. [3]
In vivo	AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. [1] AZD8055 induces ca.40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/ LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling. [4]
Incubation Time	72 to 96 hours
Kinase Assay	Cell-based determinations of mTOR inhibition, A high-throughput screening cell-based assay is developed using MDA-MB-468 cells to detect mTORC1 and mTORC2 activity. Cells are exposed for 2 hours to increasing concentrations of AZD8055. At the end of the incubation period, cells are fixed, washed, and probed with antibodies against S473 pAkt or against S235/236 phosphorylated S6 (pS6). Levels of phosphorylation are assessed using an Acumen laser scanning cytometer.
Method	Cells are exposed to AZD8055 for 72 to 96 hours and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 ug/mL acridine orange). Images are captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells are quantified. For LC3 assessment, cells are exposed to e64d/pepstatin (10 ug/mL) for 30 to 90 min before incubation with AZD8055. Cells are lysed on ice and analyzed by immunoblotting.
Solubility (25C)	DMSO 93 mg/mL, Water 2 mg/mL, Ethanol 15 mg/mL
Information	AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1, 000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy. Phase 1.
Chemical Name	(5-(2, 4-bis((S)-3-methylmorpholino)pyrido[2, 3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol
Features	First drug that inhibits both types of mTOR protein and More effective

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

S1555-10-datasheet.pdf

S1555-10-safety-datasheet.pdf